熱門資訊> 正文
Sarepta基因疗法Elevidys在两名患者死亡后收到FDA盒装警告
2025-11-15 05:24
- The US FDA has ordered a Boxed Warning be added to the labeling of Sarepta Therapeutics' (SRPT) Elevidys (delandistrogene moxeparvovec) about the risk of fatal acute liver failure for the gene therapy used for Duchenne muscular dystrophy.
- The labeling is also being updated for use only in ambulatory patients ages four and higher.
- Sarepta reported the deaths of two teenage boys who were non-ambulatory who used the therapy, first in March and then in June. In July, the company said a third patient who was taking part in an early-stage trial for a new treatment for limb-girdle muscular dystrophy died from acute liver failure.
- "In both fatal cases, patients developed markedly elevated liver enzymes and required hospitalization within two months of Elevidys infusion," the FDA said in a press release.
- The agency also removed the indication for Elevidys in non-ambulatory patients.
- Sarepta shares have suffered mightily in 2025 as a result of the deaths, and are down ~85% year to date.
More on Sarepta Therapeutics
- Sarepta Therapeutics: Why High Risk, Low Return Until Mid-To-Late 2026
- FDA Duchenne Failure Hits Sarepta Amid 3Q25 Earnings Beat
- Sarepta Therapeutics, Inc. 2025 Q3 - Results - Earnings Call Presentation
- Sarepta raised to Outperform at Mizuho on strong results
- Sarepta plunges after late-stage Duchenne trial failure
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
